Payment overview · 2025
General Payments
$180.96
5 reported records · 3 companies
Healthcare provider profile · identity verified
Kim P Kuhar
Allopathic & Osteopathic Physicians|Internal Medicine · SILVERDALE, PA · NPI 1508898396
Verified facts
What the public records show
CMS Open Payments records show Kim P Kuhar received $180.96 in general payments during 2025 across 5 reported records.
Astellas Pharma US Inc accounted for 80.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $145.02 | 80.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.84 | 10.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.10 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $99.00 | 1 |
| Food and Beverage | $81.96 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 101 |
| Losartan Potassium | Losartan Potassium | 352 | 100 |
| Lorazepam | Lorazepam | 271 | 85 |
| Sertraline Hcl | Sertraline Hcl | 260 | 69 |
| Famotidine | Famotidine | 249 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 60 |
| Omeprazole | Omeprazole | 228 | 67 |
| Lisinopril | Lisinopril | 225 | 72 |
| Simvastatin | Simvastatin | 187 | 53 |
| Metformin Hcl | Metformin Hcl | 178 | 53 |
| Gabapentin | Gabapentin | 177 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 53 |
| Furosemide | Furosemide | 152 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 37 |
| Farxiga | Dapagliflozin Propanediol | 107 | 21 |
| Synthroid | Levothyroxine Sodium | 102 | 27 |
| Valsartan | Valsartan | 99 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 24 |
| Eliquis | Apixaban | 97 | 18 |
| Trazodone Hcl | Trazodone Hcl | 94 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 25 |
| Ozempic | Semaglutide | 88 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Tramadol Hcl | Tramadol Hcl | 86 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 27 |
| Spironolactone | Spironolactone | 77 | 22 |
| Glipizide Er | Glipizide | 74 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 34 |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Allopurinol | Allopurinol | 67 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Celecoxib | Celecoxib | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Estradiol | Estradiol | 46 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Meloxicam | Meloxicam | 39 | 13 |
| Atenolol | Atenolol | 38 | suppressed |
| Carvedilol | Carvedilol | 38 | 11 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Nystatin | Nystatin | 16 | 11 |
| Trulicity | Dulaglutide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.96 · 5 records | Astellas Pharma US Inc | ABRYSVO, COMIRNATY, MOUNJARO, PREVNAR 20, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error